AR015133A1 - Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic - Google Patents

Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic

Info

Publication number
AR015133A1
AR015133A1 ARP980103547A ARP980103547A AR015133A1 AR 015133 A1 AR015133 A1 AR 015133A1 AR P980103547 A ARP980103547 A AR P980103547A AR P980103547 A ARP980103547 A AR P980103547A AR 015133 A1 AR015133 A1 AR 015133A1
Authority
AR
Argentina
Prior art keywords
crystalline form
pharmaceutical composition
carvedilol
propanol
prepare
Prior art date
Application number
ARP980103547A
Other languages
English (en)
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of AR015133A1 publication Critical patent/AR015133A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)-etilamino]-2-propanol, carvedilol que tiene el siguiente modelo de difraccion derayos X obtenido con una radiacion CuKalfa a 2theta = 9,5, 10,8, 12,0, 14,5, 19,6, 21,5, 22,3, y unespectro infrarrojo que tiene picos marcados a 3451 cm-1,en donde el punto de fusion es de aprox. 123-126*C. Sales farmacologicamente aceptables o formas opticas activas de la forma cristalina de carvedilol. Unprocedimiento para preparar y aislar una forma cristalina sustancialmente pura de la forma cristalina de carvedilol.Una composicion farmacéutica, que comprendela forma cristalina de carvedilol en una forma sustancialmente pura, como el ingrediente activo, junto con uno o más adyuvantes ovehículos farmacéuticamenteaceptables; y el uso de la composicion farmacéutica para preparar un medicamento para la profilaxis o el tratamiento de enfermedades cardíacas. La formacristalina de carvedilol se la puede utilizar para evitar y/o tratar enfermedades circulatorias y cardíacas.
ARP980103547A 1997-07-22 1998-07-21 Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic AR015133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97112491A EP0893440A1 (en) 1997-07-22 1997-07-22 Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it

Publications (1)

Publication Number Publication Date
AR015133A1 true AR015133A1 (es) 2001-04-18

Family

ID=8227094

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103547A AR015133A1 (es) 1997-07-22 1998-07-21 Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic

Country Status (32)

Country Link
EP (2) EP0893440A1 (es)
JP (1) JP2001510824A (es)
KR (1) KR100336229B1 (es)
CN (1) CN1125047C (es)
AR (1) AR015133A1 (es)
AT (1) ATE236123T1 (es)
AU (1) AU740453B2 (es)
BR (1) BR9810776A (es)
CA (1) CA2296637C (es)
CZ (1) CZ296947B6 (es)
DE (1) DE69812964T2 (es)
DK (1) DK1000027T3 (es)
ES (1) ES2195366T3 (es)
HK (1) HK1029339A1 (es)
HR (1) HRP980406A2 (es)
HU (1) HUP0003198A3 (es)
IL (1) IL133677A (es)
MA (1) MA26523A1 (es)
MY (1) MY117734A (es)
NO (1) NO313588B1 (es)
NZ (1) NZ502136A (es)
PE (1) PE96999A1 (es)
PL (1) PL191602B1 (es)
PT (1) PT1000027E (es)
RU (1) RU2202542C2 (es)
SI (1) SI1000027T1 (es)
TR (1) TR200000148T2 (es)
TW (1) TW505631B (es)
UY (1) UY25108A1 (es)
WO (1) WO1999005105A1 (es)
YU (1) YU2200A (es)
ZA (1) ZA986475B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402336C (en) * 2000-04-03 2008-03-11 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
EP1655285A1 (en) * 2000-06-28 2006-05-10 Teva Pharmaceutical Industries Ltd. Method for preparation of a crystalline form of carvedilol (form II)
KR20080064908A (ko) * 2000-06-28 2008-07-09 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
DE60212130D1 (en) * 2001-07-13 2006-07-20 Smithkline Beecham Corp Carvedilolpolymorph
ES2298401T3 (es) 2001-09-21 2008-05-16 Egalet A/S Dispersiones solidas de liberacion controlada de carvedilol.
CN1308307C (zh) * 2001-09-28 2007-04-04 弗·哈夫曼-拉罗切有限公司 假多晶型的卡维地洛
WO2003059807A2 (en) 2002-01-15 2003-07-24 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US20050261355A1 (en) 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
US7268156B2 (en) * 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
US20040151772A1 (en) 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
SI21616A (sl) * 2003-09-02 2005-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalne oblike karvedilola
US7750036B2 (en) 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1838670B1 (en) * 2004-12-09 2009-10-14 ZaCh System S.p.A. Process for the preparation of carvedilol and its enantiomers
WO2006135757A1 (en) * 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
WO2008002683A2 (en) 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten

Also Published As

Publication number Publication date
PL338432A1 (en) 2000-11-06
CN1264366A (zh) 2000-08-23
AU8631998A (en) 1999-02-16
HUP0003198A2 (en) 2001-03-28
PT1000027E (pt) 2003-07-31
DK1000027T3 (da) 2003-07-21
KR100336229B1 (ko) 2002-05-09
CZ2000221A3 (cs) 2000-05-17
AU740453B2 (en) 2001-11-01
EP0893440A1 (en) 1999-01-27
HRP980406A2 (en) 1999-04-30
YU2200A (sh) 2002-03-18
IL133677A (en) 2004-06-01
UY25108A1 (es) 2000-12-29
ZA986475B (en) 2000-01-21
CZ296947B6 (cs) 2006-08-16
MA26523A1 (fr) 2004-12-20
IL133677A0 (en) 2001-04-30
DE69812964T2 (de) 2004-03-04
WO1999005105A1 (en) 1999-02-04
BR9810776A (pt) 2000-09-19
NZ502136A (en) 2002-05-31
EP1000027A1 (en) 2000-05-17
TW505631B (en) 2002-10-11
MY117734A (en) 2004-07-31
NO313588B1 (no) 2002-10-28
KR20010022097A (ko) 2001-03-15
HUP0003198A3 (en) 2002-10-28
DE69812964D1 (de) 2003-05-08
CA2296637A1 (en) 1999-02-04
HK1029339A1 (en) 2001-03-30
NO20000301D0 (no) 2000-01-21
PE96999A1 (es) 1999-10-12
TR200000148T2 (tr) 2000-07-21
SI1000027T1 (en) 2003-10-31
JP2001510824A (ja) 2001-08-07
NO20000301L (no) 2000-01-21
CN1125047C (zh) 2003-10-22
ES2195366T3 (es) 2003-12-01
PL191602B1 (pl) 2006-06-30
RU2202542C2 (ru) 2003-04-20
EP1000027B1 (en) 2003-04-02
ATE236123T1 (de) 2003-04-15
CA2296637C (en) 2005-11-15

Similar Documents

Publication Publication Date Title
AR015133A1 (es) Una forma cristalina de (+/-)1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi)etilamino]-2-propanol, sales farmacologicamente aceptables o formas opticas de lasmismas, un procedimiento para preparar y aislar dicha forma cristalina en forma sustancialmente pura, una composicion farmaceutica que comprende dic
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
CO5570109A1 (es) Compuestos de dihidropirimidina heterociclicos
AR090143A2 (es) Composicion farmaceutica para inhibir el crecimiento de celulas anormales
SV1999000252A (es) Derivados biciclicos sustituidos utiles como agentes contra el cancer ref.pc10113abcz
ES2159591T3 (es) Composicion de liberacion controlada.
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
ECSP055684A (es) Antagonistas del receptor opiode
AR013742A1 (es) Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
RU2000103033A (ru) Термодинамически стабильная модификация 1-(4-карбазолилокси)-3-[2-(2-метоксифенокси)этиламино]-2-пропанола, способ ее получения и содержащие ее фармацевтические композиции
NO954878L (no) Pyrrolderivater
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
GEP20022763B (en) 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor
ES2056692T3 (es) Triacinas y pirimidinas trisustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2190647T3 (es) 2',2'-difluoronucleosidos para terapia inmunosupresora y combinaciones farmaceuticas.
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
PA8587201A1 (es) Derivados terapeuticos de prolina
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
AR036689A1 (es) La forma pseudopolimorfica de (+/-) 1-(4-carbazoliloxi)-3-[2-(2-metoxifenoxi) etilamino]-2-propanol o formas opticamente activas o sales farmaceuticamente aceptables de la misma, uso de la misma, una composicion farmaceuticamente aceptable que la comprende, una forma de administracion farmaceuticame
PA8451301A1 (es) Una nueva sal
MXPA01009467A (es) Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
RU98111152A (ru) Применение активного вещества флупиртина или его фармакологически приемлемых солей в качестве лекарственного средства для профилактики и лечения заболеваний, ассоциированных с повреждением клеточной системы гемопоэза
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.

Legal Events

Date Code Title Description
FB Suspension of granting procedure